From trials to clinical practice: Temporal trends in the coverage of specialized allied health services for Parkinson's disease

被引:5
|
作者
Bloem, Bastiaan R. [1 ]
Eimers, Marietta [1 ]
van Galen, Mirte S. [2 ]
Munneke, Marten [1 ]
Darweesh, Sirwan K. L. [1 ,3 ]
机构
[1] Radboud Univ Nijmegen, Donders Inst Brain, Dept Neurol Cognit & Behav, Med Ctr, Nijmegen, Netherlands
[2] Vektis CV, Zeist, Netherlands
[3] Erasmus MC Univ Med Ctr, Dept Epidemiol, Rotterdam, Netherlands
关键词
disorders; movement disorders; neurological; Parkinson' s disease; scaling of healthcare innovations; specialized allied health services; OCCUPATIONAL-THERAPY; CARE;
D O I
10.1111/ene.14627
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and purpose To determine how the coverage of specialized allied health services for patients with Parkinson's disease (PD) has developed in the Netherlands since the publication of trials that demonstrated cost-effectiveness. Methods We used healthcare expenditure-based data on all insured individuals in the Netherlands to determine the annual proportion of patients with PD who received either specialized or generic allied health services (physiotherapy, occupational therapy, speech-language therapy) in 2 calendar years separated by a 5-year interval (2012 and 2017). Specialized allied health services were delivered through the ParkinsonNet approach, which encompassed professional training and concentration of care among specifically trained professionals. Results Between 2012 and 2017, there was an increase in the number of patients with any physiotherapy (from 17,843 [62% of all patients with PD that year] to 22,282 [68%]), speech-language therapy (from 2171 [8%] to 3378 [10%]), and occupational therapy (from 2813 [10%] to 5939 [18%]). Among therapy-requiring patients, the percentage who were treated by a specialized therapist rose substantially for physiotherapy (from 36% in 2012 to 62% in 2017; chi(2) = 2460.2; p < 0.001), speech-language therapy (from 59% to 85%; chi(2) = 445.4; p < 0.001), and occupational therapy (from 61% to 77%; chi(2) = 231.6; p < 0.001). By contrast, the number of patients with generic therapists did not change meaningfully. By 2017, specialized care delivery had extended to regions that had been poorly covered in 2012, essentially achieving nationwide coverage. Conclusions Following the publication of positive trials, specialized allied healthcare delivery was successfully scaled for patients with PD in the Netherlands, potentially serving as a template for other healthcare innovations for patients with PD elsewhere.
引用
收藏
页码:775 / 782
页数:8
相关论文
共 50 条
  • [21] The allied health profession role in work with people with Parkinson's disease
    Heisters, Daiga
    INTERNATIONAL JOURNAL OF THERAPY AND REHABILITATION, 2010, 17 (11): : 566 - 567
  • [22] Identifying and Controlling Variability in Digital Health Measures in Parkinson's disease Clinical Trials
    Roussos, G.
    Bhatnagar, R.
    Burton, J.
    Cosman, J.
    Derungs, A.
    Dowling, A.
    Fisher, K.
    Hill, D.
    Kilambi, K. Praneeth
    Evers, L.
    Mehrotra, N.
    Minchik, M.
    Muller, M.
    Herrero, T. Ruiz
    Sardar, S.
    Stephenson, D.
    MOVEMENT DISORDERS, 2021, 36 : S150 - S150
  • [23] Ongoing clinical trials on Parkinson's disease in Europe
    Eggert, K.
    ACTA NEUROLOGICA SCANDINAVICA, 2008, 117 (01): : 65 - 65
  • [24] Placebo effects in Parkinson's disease clinical trials
    Goetz, CG
    Leurgans, S
    Raman, R
    Stebbins, GT
    NEUROLOGY, 1998, 50 (04) : A71 - A71
  • [25] Neuroprotection in Parkinson's disease: Clinical trials - Discussion
    Hunot
    Stocchi
    Keiburtz
    Tatton
    Olanow
    Brooks
    Rascol
    Beal
    Marek
    Schapiro
    ANNALS OF NEUROLOGY, 2003, 53 : S97 - S99
  • [26] Issues in neuroprotection clinical trials in Parkinson's disease
    Kieburtz, K
    NEUROLOGY, 2006, 66 (10) : S50 - S57
  • [27] Minority enrollment in Parkinson's disease clinical trials
    Schneider, Myra G.
    Swearingen, Christopher J.
    Shulman, Lisa M.
    Ye, Jian
    Baumgarten, Mona
    Tilley, Barbara C.
    PARKINSONISM & RELATED DISORDERS, 2009, 15 (04) : 258 - 262
  • [28] Exclusion of older patients from randomized clinical trials in Parkinson's disease
    Klosowska, Danuta
    Fiszer, Urszula
    Dulski, Jaroslaw
    Gorski, Andrzej
    Borysowski, Jan
    GEROSCIENCE, 2024, 46 (04) : 3819 - 3830
  • [29] From clinical trials to clinical practice in cerebrovascular disease
    Hachinski, V
    5TH CONGRESS OF THE EUROPEAN SOCIETY FOR CLINICAL NEUROPHARMACOLOGY, 2000, : 139 - 142
  • [30] Identifying educational needs of interdisciplinary allied health professionals for Parkinson's disease
    Nelson, N
    Trail, M
    Lai, E
    GERONTOLOGIST, 2005, 45 : 400 - 401